Protocatechuic aldehyde inactivates STAT3 through disrupting the STAT3-JAK1 interaction in epidermal keratinocyte and improves atopic dermatitis-like skin inflammation
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115403 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Xiaoxuan Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu 610106, China; Natural Products Chem-bio Innova…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Keratinocytes, Dermatitis, Atopic, Janus Kinase 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Shanghai Rising-Star Program, National Natural Science Foundation of China, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Protocatechuic aldehyde (PA) is an active compound of Salvia miltiorrhiza (Danshen), a traditional Chinese herb wildly used for inflammatory skin diseases therapy. STAT3 activation plays a pivotal role in multiple inflammatory cutaneous diseases. We previously reported that topical treatment with PA ameliorated psoriasis-like skin inflammation, a typical Th1-mediated inflammatory skin disease, by inactivating STAT3.However, the mechanisms of STAT3 inactivation by PA remain unknown. This study evaluated the therapeutic effect on atopic dermatitis, a Th2-mediated inflammatory skin disease, which is highly associated with STAT3 overactivation. And further addressed the molecular mechanisms that PA inhibited JAK1 activation and subsequently led to disruption of the interaction between STAT3 and JAK1, thus resulting in STAT3 inactivation in keratinocyte. The transcription repression of IL-8 and TNF-α by PA in the AD-like epidermal keratinocyte is STAT3-depedent. Our results suggested that PA could be potentially used for treating STAT3-activation-associated inflammatory skin diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu 610106, China; Natural Products Chem-bio Innovation Center, Chengdu 8 University, Chengdu 610106, China; School of Fo…
- Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu 610106, China; Natural Products Chem-bio Innovation Center, Chengdu 8 University, Chengdu 610106, China; School of Ph…
- Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China. Electronic address: drlifulun@163.com.
- Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu 610106, China; Natural Products Chem-bio Innovation Center, Chengdu 8 University, Chengdu 610106, China; School of Ba…
Förderung
- Shanghai Rising-Star Program
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
Zitieren
APA
Yang, X., Zhou, Q., Liang, L., Kang, L., Yang, J., Li, X., Li, F., & Deng, Y. (2025). Protocatechuic aldehyde inactivates STAT3 through disrupting the STAT3-JAK1 interaction in epidermal keratinocyte and improves atopic dermatitis-like skin inflammation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115403
Vancouver
Yang X, Zhou Q, Liang L, Kang L, Yang J, Li X, et al. Protocatechuic aldehyde inactivates STAT3 through disrupting the STAT3-JAK1 interaction in epidermal keratinocyte and improves atopic dermatitis-like skin inflammation. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115403
BibTeX
@article{Yang2025,
author = {Yang, Xiaoxuan and Zhou, Qian and Liang, Lizhen and Kang, Liang and Yang, Jie and Li, Xiaoya and Li, Fulun and Deng, Yu},
title = {Protocatechuic aldehyde inactivates STAT3 through disrupting the STAT3-JAK1 interaction in epidermal keratinocyte and improves atopic dermatitis-like skin inflammation},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115403}
}
EUVIMED